Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients

Phase 2 Completed 14 enrolled Jean Yuh Tang Epidermolysis Bullosa Research Partnership · collab Vyne Therapeutics Inc. · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).

Timeline

Start: 2016-08-31
Primary completion: 2018-06-28
Completion: 2018-07-27

Publications

Results Chiou AS, Choi S, Barriga M, Dutt-Singkh Y, Solis DC, Nazaroff J, Bailey-Healy I, Li S, Shu K, Joing M, Kwon P, Tang JY. Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial. J Am Acad Dermatol. 2020 Jun;82(6):1415-1421. doi: 10.1016/j.jaad.2019.09.014. Epub 2019 Sep 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Serlopitant	Small molecule	5 mg	Oral

Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients

Summary

Timeline

Publications

Drugs

Indications